Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward
Gastrointestinal stromal tumor (GIST) represents a paradigm for clinically effective targeted inhibition of oncogenic driver mutations in cancer. Five drugs are currently positioned as the standard of care for the treatment of advanced or metastatic GIST patients. This is the result of continuous, d...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publishing
2021-01-01
|
| Sarja: | Therapeutic Advances in Medical Oncology |
| Linkit: | https://doi.org/10.1177/1758835920986498 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|